The most commonly reported side effects of bortezomib include plasma cell myeloma, off label use, and neuropathy peripheral, based on 87,654 FDA adverse event reports from 2004 to 2025. 3.9% of reports found the drug to be ineffective.
Percentages show how often each reaction appears relative to total reports for bortezomib.
These are voluntary reports and do not establish that bortezomib caused these reactions.
Report severity
Seriousness is determined by the reporter, not by OpenClaim.
Other drugs that appear in adverse event reports alongside bortezomib. Drugs flagged as a suspected cause appear in the first column. Drugs taken at the same time but not suspected appear in the second.
Also suspected
Taken alongside
Co-occurrence in adverse event reports does not establish a drug interaction. Patients often take multiple medications, and these lists reflect prescribing patterns rather than causal relationships. Consult a healthcare provider about potential drug interactions.
36.5% of bortezomib adverse event reports involve female patients and 45.2% involve male patients. The largest age group is elderly at 55%. These figures reflect who reports side effects, not underlying risk.
Sex
Age group
Conditions and purposes for which patients were taking bortezomib when the adverse event was reported.
Showing 15 of 877 indications
Bortezomib is sold under the brand name Velcade.
An upward trend reflects increased FAERS reporting overall, not necessarily increased risk.
Ask OpenClaim about your specific drug combination. Get a sourced report using FDA data, drug labels, and medical literature.